Anatara Lifesciences Ltd has released a press release.
GaRP Irritable Bowel Syndrome Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Anatara Lifesciences Ltd on 6ix
Earlier from Anatara Lifesciences
- $626,000 received in R&D Tax Incentive for FY24
- Appendix 4E & Financial Report 30 June 2024
- Appendix 4C & Q4 FY24 Activities Report
- Anatara successful placement for $1.0M
- Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2
Later from Anatara Lifesciences
- Anatara's GaRP granted EU patent
- GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update
- Appendix 4C & Q1 FY25 Activities Report
- Chair's Address to Shareholders
- Successful Placement of $660k and Share Purchase Plan
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences